Data Characteristics
Bioequivalence clinical trial pre-screening data primarily originates from published clinical trial reports, drug labels, pharmacokinetic (PK) study data, and regulatory review documents. This data updates infrequently, typically with new drug approvals or generic drug submissions. Document structures are relatively fixed, often structured or semi-structured text. They include study protocols, subject information, dosing regimens, biological sample analysis results, PK parameters (e.g., Cmax, AUC0-t, AUC0-inf), and statistical analysis reports. Fields include drug name, dose, dosage form, subject characteristics, sampling time points, plasma concentration values, and statistical indicators. Units strictly follow international standards; for example, plasma concentrations are typically in ng/mL, and time is in h.
Constraints Imposed by These Characteristics on Vector Models and Indexing
The fixed nature and infrequent updates of bioequivalence data mean that vector model training and index construction can use a stable baseline, avoiding frequent retraining. The high degree of document structure facilitates accurate field extraction and metadata tagging during data preprocessing, improving the precision of vector recall. Numerical fields like PK parameters require special handling, such as vectorization of numerical ranges or combination with text descriptions, to ensure that numerical differences are effectively perceived by the model. Strict unit specifications require unit standardization during data cleaning to prevent misinterpretations due to inconsistent units. These constraints collectively point to a need for refined data preprocessing and diverse vectorization strategies to ensure the model accurately understands and matches key information in bioequivalence trials.
Configuration Settings
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk size (Segment Length) | 500-800 characters | Ensures each segment contains complete key information, such as a full PK parameter description or statistical conclusion. |
Chunk overlap (Segment Overlap) | 100 characters | Maintains contextual continuity, preventing critical information from being truncated by segmentation. |
Similarity threshold (Similarity Threshold) | Calibrate based on actual measurements | Adjust based on the relevance of recalled bioequivalence reports to ensure highly relevant results are recalled. |
Recall count (Number of Retrieved Items) | 10-20 items | Balances comprehensive recall with avoiding excessive irrelevant results, improving subsequent re-ranking efficiency. |
maxContext | 3000-4000 tokens | Adapts to mainstream large language model context windows, ensuring multiple retrieved results can be accommodated for comprehensive analysis. |
Vector Database Type | PostgreSQL with pgvector | Balances ease of deployment with production environment stability, suitable for medium-scale data volumes. |
Three Common Pitfalls
- Recalled results do not include critical PK parameters: This occurs when numerical data is not effectively processed during vectorization, or when the segmentation strategy separates numerical values from their descriptions.
- Pre-screening results include non-bioequivalence studies: This happens when document metadata is not fully utilized for filtering during index construction, leading to the recall of general clinical trial reports.
- Excessive pre-screening time or query timeouts: This is due to insufficient vector database index optimization, or when
Recall count(Number of Retrieved Items) is set too high, leading to an excessive query load.
How to Verify Configuration
- Execute queries containing key PK parameters and drug names. Verify that the recalled results include all relevant bioequivalence reports.
- Check the
metadatafield of the recalled results to confirm accurate inclusion of key information such as drug name, dosage form, and study type. - Simulate actual pre-screening scenarios to test the average response time for multiple queries, ensuring it is within an acceptable range.
- Evaluate the recall and precision of pre-screening results on a test set, setting acceptable thresholds based on business requirements.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.